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RESEARCH ARTICLES
Rod Outer Segment Development Influences AAV-Mediated
Photoreceptor Transduction After Subretinal Injection
Lolita Petit,1 Shan Ma,1 Shun-Yun Cheng,1 Guangping Gao,3 and Claudio Punzo1,2,*
1Department of Ophthalmology and Gene Therapy Center, 2Department of Neurobiology, and 3Department of Microbiology and Physiological Systems
and Gene Therapy Center, University of Massachusetts Medical School, Worcester, Massachusetts.
Vectors based on the adeno-associated virus (AAV) are currently the preferred tools for delivering genes
to photoreceptors (PR) in small and large animals. AAVs have been applied successfully in various
models of PR dystrophies. However, unknown barriers still limit AAV’s efficient application in several
forms of severe PR degenerations due to insufficient transgene expression and/or treated cells at the
time of injection. Optimizations of PR gene therapy strategies will likely benefit from the identification
of the cellular factors that influence PR transduction. Interestingly, recent studies have shown that the
AAV transduction profile of PRs differs significantly between neonatal and adult mouse retinas after
subretinal injection. This phenomenon may provide clues to identify host factors that influence the
efficiency of AAV-mediated PR transduction. This study demonstrates that rod outer segments are
critical modulators of efficient AAV-mediated rod transduction. During retinal development, rod
transduction correlated temporally and spatially with the differentiation order of PRs when vectors
were introduced subretinally but not when introduced intravitreally. All subretinally injected vectors
had an initial preference to transduce cones in the absence of formed rod outer segments and then
displayed a preference for rods as the cells matured, independently of the expression cassette or AAV
serotype. Consistent with this observation, altered development of rod outer segments was associated
with a strong reduction of rod transduction and an increase in the percentage of transduced cones by 2-
to 2.8-fold. A similar increase of cone transduction was observed in the adult retinal degeneration 1 (rd1)
retina compared to wild-type mice. These results suggest that the loss of rod outer segments in diseased
retinas could markedly affect gene transfer efficiency of AAV vectors by limiting the ability of AAVs to
infect dying rods efficiently. This information could be exploited for the development of more efficient
AAV-based PR gene delivery procedures.
Keywords: AAV, retina, photoreceptors, cones, rods, gene therapy
INTRODUCTION
RECOMBINANT AAV SEROTYPE 2 (AAV2) is currently
being evaluated in Phase 1/2 and 3 gene therapy
clinical trials for treating diverse inherited retinal
diseases involving the retinal pigment epithelium
(RPE), such as Leber congenital Amaurosis 2,1–9
retinitispigmentosa,10 andchoroideremia.11,12 These
studies demonstrate that subretinal delivery of AAV
is safe and can provide rescue of vision-guided be-
havior in patients with advanced disease at least for
several years.13 However, broader application of ret-
inal gene therapy will require efficient transduction of
other retinal cells, in particular photoreceptors (PR).
The ability of various AAV serotypes to trans-
duce PRs has been evaluated in small14–18 and
large15,19–26 animals. Among these, pseudotypes
-2/5, -2/7, -2/8, -2/9, and -2/rh10 were found to have
the highest transduction efficiencies for PRs after
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E-mail: Claudio.Punzo@umassmed.edu
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subretinal delivery.27,28 These vectors have been
used to drive persistent transgene expression suc-
cessfully, resulting in improvements of the retinal
structure and/or function in a number of animal
models of PR dystrophies, in particular in models of
slow PR death.13 Yet, in models of severe PR de-
generation, many PR therapies have not been very
effective at rescuing PR over the long term. This is
likely due to the difficulties in treating sufficient
cells and/or expressing therapeutic levels of the
transgene in a timely manner. In support of this
idea, AAV8-based vectors have provided higher
benefits than AAV5 in different disease models of
primary PR dystrophies, such as in the retinal de-
generation 10, the Rpgrip1-/- (retinitis pigmentosa
GTPase regulator interacting protein 1), the
Guy2e-/- (retinal guanylate cyclase 1), the Aipl1-/-
(aryl hydrocarbon interacting protein like 1), and
the Rho-/- (rhodopsin) mice, consistent with the
superior ability of AAV8 to transduce PRs more
efficiently and thus delivering higher transgene
levels when compared to AAV5 (for review, see
Petit et al.13). Moreover, a recent study has shown
that a therapeutic transgene can halt degenera-
tion, regardless of the severity of PR loss if acti-
vated optimally in all PR cells.29 These results
point to the importance of improving PR trans-
duction efficiency to maximize clinical impact, and
indicate that further development of retinal gene
therapy will likely benefit from a better under-
standing of the potential host cell factors that re-
strict PR transduction in vivo. However, basic
aspects of AAV–PR interactions are still unknown,
and mechanisms affecting PR transduction after
subretinal injection remain largely unexplored.20
Interestingly, recent reports have shown that
after subretinal injection, the AAV transduction
profile of PR cells changes dramatically between
neonatal and adult mice.30–34 In particular, injec-
tion of AAV2/8 at postnatal day (PND) 0 results
primarily in cone transduction (*100% of cones,
almost no rods),32–34 whereas the vast majority of
transduced cells in adults are rods.14,15,32 The
current study took advantage of this shift in tro-
pism to identify host factors critical for AAV-
mediated PR transduction. Using 13 different AAV
serotypes, cone and rod transduction were specifi-
cally assessed after AAV subretinal delivery in the
developing retina and in two murine models of rod-
cone dystrophies that display either an arrest of
PR outer segment development or a rapid loss of
rod cells. Irrespective of the serotype tested, it was
found that all vectors preferentially transduced
cones when delivered at PND1, whereas delivery at
PND21 resulted in a decrease in the percentage of
transduced cones and a dramatic increase in the
percentage of transduced rods. Additional injec-
tions at PND5 and PND10 showed that rod trans-
duction temporally and spatially correlates with
the development of their inner and outer segments.
Furthermore, in mutant mouse models that lack
rod outer segments or rod PR cells, a preferential
transduction of cones was observed. Together,
these findings indicate that the access of AAV
vectors to PR cells through their segments is a key
factor for PR transduction upon subretinal deliv-
ery. Additionally, the data suggest that mature
rods and cones may compete for AAV access. These
observations begin to define a new paradigm for
AAV–PR interactions upon subretinal delivery,
which should impact the development of more ef-
ficient AAV-based PR gene delivery procedures by
providing an understanding of host factors re-
quired for successful AAV transduction.
MATERIAL AND METHODS
Plasmid construction, AAV vector production,
and purification
Recombinant AAV2/5-CMV-GFPd, AAV2/5-CMV-
H2bGFP, AAV2/5-CMV-Cre, AAV2/5-pQCMV-H2b
GFP, and AAV2/5-mCAR-H2bGFP were produced
usingthepAAV2-CMV-GFPd,pAAV2-CMV-H2bGFP,
pAAV2-CMV-Cre, pAAV2-pQCMV-H2bGFP, or
pAAV2-mCAR-H2bGFPplasmids, respectively. The
pAAV2-CMV-GFPd plasmid expresses the destabi-
lizedGFP cDNA under the control of a human CMV
enhancer/promoter, a human b-globin intron and an
SV40 polyA signal, flanked by two AAV2 inverted
terminal repeat sequences. The pAAV2-CMV-
H2bGFP plasmid expresses a histone 2B fused GFP
(nuclear GFP). It was constructed by replacing the
GFPd cDNA with the H2bGFP sequence derived
from the parental pQCMV-H2bGFP plasmid. The
pAAV2-CMV-Cre plasmid expresses a Cre re-
combinase. It was constructed by replacing the
GFPd cDNA with theCre sequence derived from the
parental pQCMV-H2bGFP-I-Cre plasmid. The
pAAV2-mCAR-H2bGFP plasmid was made by repla-
cing the CMV promoter with the mouse cone arrestin
(mCAR) promoter from the parental pQCMV-
H2bGFP plasmid.35
scAAV1, -2, -3b, -4, -5, -6, -7, -8, -9, rh8, rh10, rh39,
and rh43 expressing enhanced GFP (eGFP) under
the control of the CB6 promoter were produced using
the pAAVsc-CB6-eGFP plasmid, which bears a CB6
promoter, a rabbit globin polyA, and engineered ITRs
for scAAV vector. The CB6 sequence was previously
described36 and includes a CMV enhancer/beta-actin
(CB) promoter with a CMV IE enhancer.
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AAV2/5-CMV-GFPd, AAV2/5-CMV-H2bGFP,
AAV2/5-CMV-Cre, AAV2/5-pQCMV-H2bGFP, and
AAV2/5-mCAR-H2bGFP were produced in the
Punzo laboratory by triple transfection of 293 cells
according to previously reported methods37 and
purified by two rounds of CsCl2 ultracentrifuga-
tion. scAAV vector production was carried out by
the Vector Core of the Horae Gene Therapy Center
of UMASS Medical School (Worcester, MA).38 Viral
vector titers were determined simultaneously for
all batches by quantitative real-time PCR (qPCR)
with primers directed toward SV40pA (forward: 5¢-
CGAGTGCTTTATTTGTGAAATTTG-3¢; reverse:
5¢-GGGGTTCCTTGTAGTTAATGA-3¢) or eGFP
(forward: 5¢-AGCAAAGACCCCAACGAGAA-3¢; re-
verse: 5¢-GGCGGCGGTCACGAA-3¢) and expressed
as vector genome per milliliter (vg/mL). The final
vector titers were between 8.1·1012 and 5.1·1013
vg/mL (Table 1).
Animals
The CD1, Ai9 Cre reporter mice, andPde6brd1/rd1
mice were purchased from the Jackson Laboratory.
The M-opsin-Cre mice39 (cone-specific Cre line) and
the rhodopsin knockout (Rho-/-) mice40 were
provided by Yun Z. Le (University of Oklahoma
Health Sciences Center) and Janis Lem (Tufts
University, Boston), respectively. Ai9+/-_MCre+
mice were generated by crossing MCre+ mice
with the Ai9 Cre reporter mice. Pde6brd1/+_Ai9+/-
mice were generated by crossing rd1 mice and
Ai9 mice. Heterozygotes were mated to produce
Pde6brd1/rd1/+_Ai9+/- mice.
All animals were maintained at UMASS Medical
School under a 12 hour/12 hour light/dark cycle with
unrestricted access to food and water. Lighting con-
ditions were kept constant in all cages, with illumi-
nationrangingbetween10and15lux.Allexperiments
involving mice were conducted in compliance with the
AssociationforResearch inVisionandOphthalmology
statement for the use of animals in ophthalmic and
vision research. All procedures were approved by In-
stitutional Animal Care and Use Committee of
UMASS Medical School.
Subretinal administration of rAAV vectors
The same experimenter (L.P.) performed all
subretinal injections of AAV vectors. Subretinal
injection of AAV vectors was performed using
a trans-scleral approach through the posterior
part of the sclera, as previously described,41 with
the following modifications. Injections were per-
formed using thin-wall beveled glass micropipettes
(Clunbury Scientific LLC) without sclerotomy. In
mice older than PND1, a small hole was made at
the transition of the cornea and sclera with a 33-
gauge needle before the injection in order to release
intraocular pressure and allow for the formation of
a vector bleb upon subretinal injection. This pro-
cedure allowed the vector bleb to occupy 40–60% of
the retinal surface without injection-related dam-
age. Fast green dye was added to the AAV prepa-
rations at a final concentration of 0.1% as a tracer
to visualize the location of injection and thus en-
sure that AAV vectors were injected into the sub-
retinal space. Mice received 0.5–0.75lL of vectors
at PND1, 1–1.5 lL of vectors at PND5–10, and 1.5–
2.5lL of vectors at PND21.
Intravitreal administration of rAAV vectors
Intravitreal injections were performed in PND1
mice, as previously described,41 using the same
glass micropipettes (Clunbury Scientific LLC) in-
troduced through the cornea-scleral margin. Fast
green dye was added to AAV preparations at a final
concentration of 0.1% as a tracer to visualize the
location of injection and thus ensure that AAV
vectors were injected into the intravitreal cavity.
Mice received 0.75–1lL of vectors.
Quantification of cone and rod transduction
In all cases, the analysis was performed 3 weeks
post AAV injection. The total number of retinas
analyzed in each experimental group is indicated
in Table 1. The efficiency of retinal transduction
was first assessed under an inverted fluorescent
microscope, and only retinas that displayed native
GFP fluorescence in >30% of the total retinal sur-
face were processed for further analysis. All images
were acquired with the Leica DM5500 fluorescent
microscope equipped with a motorized stage for
tiling and z-stack image acquisition and deconvo-
lution software for confocal-like image quality.
Quantification of cone and rod transduction in
selected retinas was performed using three inde-
pendent methods. First, for each group of injected
mice, a minimum of two retinas were entirely sec-
tioned (20 lm/section) and collected serially on five
slides, such that each slide contained a represen-
tation of the entire eye. A minimum of two slides
were processed for immunohistochemistry using
Cy3-labeled peanut agglutinin lectin (PNA; 1:500;
Vector Laboratories) and rabbit anti-cone arrestin
(1:500; EMD Millipore). Images were taken from 5–
10 sections at 40· over the entire transduced area
at different focal plans (z stacks) using epi-
fluorescence microscopy (Supplementary Fig. S1;
Supplementary Data are available online at
www.liebertpub.com/hum). The acquired epifluo-
rescent images were then deconvolved in order to
466 PETIT ET AL.
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obtain confocal-like resolution by eliminating the
out-of-focus signal that could be misinterpreted as
colocalization (Supplementary Fig. S1a). Cone
quantification was performed in one selected z
stack for each image, based on the colocalization
of the GFP signal with the cone arrestin marker
(usually at the level of cell nuclei). Rod quantifi-
cation was performed within the same z stack for
each image by manually counting the number of
total GFP+ PRs and the number of GFP+ cones per
image, and by determining through an automated
counting algorithm the total number of PR nuclei
in the outer nuclear layer (ONL) of the same image
using the Imaris software package (Supplemen-
tary Fig. S1b). Rod transduction was then calcu-
lated as an average per eye and per group by
determining the ratio of the number of total GFP+
PRs – number of GFP+ cones to the total number of
PR nuclei – number of cone cells per image.
Second, for groups of mice injected with AAV-
dGFP or AAV-eGFP vectors, cone quantification
was also performed on retinal flat mounts stained
with the following lectins/antibodies: Cy3-labeled
PNA (1:500; Vector Laboratories), rabbit anti-cone
arrestin (1:500; EMD Millipore; AB15282), rabbit
anti-LM opsin (1:500; EMD Millipore; AB5405),
and goat anti-S opsin (1:500; Santa Cruz Bio-
technology; SC-14363). For each flat mount, four to
six representative 100lm2 areas within the trans-
duced area (center and periphery) were analyzed.
The percentage of transduced cones was determined
as an average per eye and per group by quantifying
the number of GFP+ cones over the total number of
cones in the same areas. This quantification was
performed at the level of cone segments, where GFP
fluorescence in cones was unambiguously sur-
rounded by PNA staining (Supplementary Fig. S1c).
Third, AAV5-CMV-H2bGFP and AAV5-pQCMV-
H2bGFP vectors were also evaluated in Ai9+_MCre
mice, which express CRE-mediated td-Tomato
(red) in the entire cone cell bodies (Supplementary
Fig. S1d).
Cell lines
Two different Chinese hamster ovary (CHO) cell
lines were used to confirm the specificity of the
lectins used in this study. These include the pa-
rental cell line Pro5 and sialic-acid deficient cell
line Lec2. Both cell lines were kindly provided by
Miguel Sena-Esteves (UMASS Medical School).
Cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal
bovine serum and 1% streptomycin and main-
tained at 37C with 5% CO2. Cells were seeded at
105 cells/well in 12-well plates prior to treatment
for 1 h at 37C with DMEM alone or DMEM sup-
plemented with 50 mIU/mL of neuraminidase type
III from Vibrio cholerae (Sigma–Aldrich; N7785).
Cells were then washed three times with DMEM,
once with PBS-1· and fixed with 4% PFA for
10 min. Cells were subjected to staining for 1 h in
PBS-1 ·at room temperature (RT) using the fol-
lowing lectins: Cy2- or Cy3-labeled PNA (1:500),
Cy2-conjugated Maackia amurensis lectin (MAL1;
1:500), biotinylated Erythrina cristagalli lectin
(ELC; 1:500), and Cy5-conjugated wheat germ ag-
glutinin (WGA; 1:500) all from Vector Labora-
tories. After three washes with ice-cold PBS-1· to
remove unbound lectins, ECL was visualized using
Streptavidin-Cy5 (Molecular Probes). Cells were
imaged using an inverted fluorescence microscope.
Lectin analysis
of the inter-photoreceptor matrix
Analysis of the inter-photoreceptor matrix (IPM)
was performed on retinal sections, flat mounts, and
explants from Ai9_MCre+ mice euthanized at
PND1, PND5, PND10, PND14, and PND21, and on
retinal flat mounts from Rho-/- mice euthanized at
PND21. Three eyes were used for each experi-
mental group. Retinal sections and retinal flat
mounts were processed and stained, as previously
described, for the cell culture experiments, with
the following panel of lectins in PBS1X: PNA
(1:500; Vector Laboratories), MAL1 (1:500; Vector
Laboratories), ELC (1:500; Vector Laboratories),
and WGA (1:500; Vector Laboratories). For retinal
explants treated with neuraminidase, retinas were
dissected in cold DMEM and incubated in either
DMEM alone or DMEM with 50 mIU/mL of neur-
aminidase type III from V. cholerae (Sigma–
Aldrich; N7785) for 1 h at 37C. Retinal explants
were then washed three times with cold DMEM,
once with cold PBS-1· , and fixed in 4% PFA for
30 min. Retinal explants were subjected to lectin
staining for 1 h in PBS-1· at RT. After three washes
with ice-cold PBS-1· to remove unbound lectins,
retinal explants were flat mounted and analyzed by
fluorescence microscopy (Leica DM5500).
AAV-binding assay and qPCR
AAV-binding assay was performed on three bi-
ological samples and repeated two to four times
with retinal explants from PND1 and PND21 CD1
mice. Retinas were dissected in cold DMEM and
incubated in either DMEM with or without neur-
aminidase for 1 h at 37C. Retinal explants were
then washed three times with cold DMEM, and
pre-chilled at 4C for 1 h in 500lL of DMEM. AAV
vectors were added at 1 ·1010 vg/well, and explants
IMPACT OF RETINAL DEVELOPMENT ON AAV TRANSDUCTION 467
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were incubated at 4C for 1 h. Retinal explants
were then washed three times with cold DMEM
and once with cold PBS-1· to remove unbound AAV
particles. Total DNA was extracted using the
DNeasy Blood and Tissue Kit (Qiagen). AAV ge-
nome copies were quantified by real-time PCR with
the aforementioned primers for the SV40pA or
eGFP sequence. AAV vector genomes (vg) were
normalized to the number of retinal cells, using
primers complementary to the mouse beta actin
DNA (forward: 5¢-ACTGGGACGACATGGAGAAG-
3¢; reverse: 5¢-GGGGTGTTGAAGGTCTCAAA-3¢).
Samples were run in triplicate. The results were
expressed as mean AAV vg per genome DNA.
Localization of AAV binding
to retinal photoreceptors
Localization of AAV particles was assessed af-
ter subretinal injection of PND1 and PND21
Ai9_MCre+ mice with scAAV8 or scAAV9 vectors.
Eyes injected with PBS-1· were used as negative
controls. One hour post injection, animals were eu-
thanized and retinas processed for flat mount, as
previously described.41 Retinas were incubated over-
night at 4C with polyclonal rabbit antibodies raised
against intact capsids of AAV8 or AAV9 at 1:500 in
blocking solution (kindly provided by G.G.). Sections
were then incubated with a Cy2-conjugated second-
ary anti-rabbit antibody (Jackson ImmunoResearch;
1:500) for 2 h at RT. Results were analyzed by fluo-
rescence microscopy (Leica DM5500).
Statistical analysis
All data are expressed as mean– standard devi-
ation (SD). All statistical comparisons use Stu-
dent’s t-test, with p<0.05 considered as statistically
significant in all comparisons.
RESULTS
Subretinal injection of AAV5 at PND1
predominantly targets cone photoreceptors
Recent reports showed that subretinal injection
of AAV8 into PND0 mice results primarily in cone
transduction, whereas the vast majority of trans-
duced cells after subretinal injection in adult mice
are rods.32–34 To demonstrate further that PR
postnatal development impacts the pattern of PR
transgene expression, neonatal mice (PND1) were
subretinally injected with 6 ·108–1.2 ·109 vg of
single-stranded (ss) AAV2/5-CMV-dGFP (Table 1
and Supplementary Fig. S2a). AAV5 was chosen
because this serotype (i) has been shown to signif-
icantly target PR cells in the adult mouse,14,15,18
cat,26 dog,23,42,43 pig,15,22 and nonhuman prima-
te21; (ii) has been used successfully to restore reti-
nal function and preserve retinal structure in
various models of PR diseases13; and (iii) is cur-
rently planned in upcoming Phase I–II clinical
trials for the treatment of PR diseases.13 Mice with
successful subretinal injections were euthanized 3
weeks post injection (wpi), at PND21, after PR
differentiation and maturation is completed (Fig. 1
and Supplementary Fig. S2). As previously de-
scribed,30,33,34 subretinal injections at PND1 yiel-
ded GFP expression throughout the entire retinal
surface (Fig. 1a and Supplementary Fig. S2a), pre-
sumably because the interactions between the RPE
and the PR outer segments that could limit the
spread of the vector have not yet formed at PND1.
Robust transduction of RPE was observed across the
retina (Supplementary Fig. S2b). High levels of GFP
were also detected in the ONL, which contains rod
and cone PR nuclei (Fig. 1c and Supplementary
Fig. S2b), and in the corresponding PR segments
(Fig. 1a and c and Supplementary Fig. S2b). Im-
munostaining with cone-specific markers (PNA and
cone arrestin) revealed that the majority of the GFP+
cells were also positive for the cone-specific markers
(Fig. 1a and c and Supplementary Fig. S2b). Hence,
as predicted, the transduction of PRs was essentially
relegated to cones when considering the percentage
of GFP+ cells (cones: 69.1–7.4%; rods: 2.7–3.1%). L/
M and S cones were equally transduced (Supple-
mentary Fig. S3).
To rule out an influence of factors such as inhi-
bition of CMV promoter activity or dGFP steady
state level on the final transgene expression pat-
tern, PR transduction was analyzed in mice in-
jected at PND1 with five additional AAV5 vectors.
These vectors carry different transgenes and/or
ubiquitous or PR-specific promoters: AAV5-CMV-
H2bGFP, AAV5-CMV-Cre, AAV5-mCAR-H2bGFP,
AAV5-pQCMV-H2bGFP, as well as a self-
complementary (sc) AAV5-CB6-eGFP (Table 1).
Though some construction-dependency was noted,
tropism was similar for all vectors examined
(Fig. 1b and c and Supplementary Fig. S2b). Hence,
the findings suggest that the absence of efficient rod
transduction following subretinal administration
at PND1 is not dependent on factors that alter
vector genome expression, as well as second-strand
synthesis in the transduced cells, but rather on
differences in entry of AAV into cones and rods at
the time of delivery. Consistent with that, AAV8
vectors carrying different promoters, such as AAV-
hRK1-GFP, AAV-mCAR-GFP, or AAV-CMV-GFP,
have also been seen to drive transgene expression
predominantly in cones after subretinal injection in
PND0 neonate mice.33,34 Moreover, efficient trans-
468 PETIT ET AL.
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fection of rods has been previously obtained after
PND0 electroporation of pCMV-H2bGFP,41 a plas-
mid DNA that carries the same expression cassette
as the AAV5-CMV-H2bGFP. Finally, a higher
number of GFP+ rods was observed after adminis-
tration of higher doses of AAV5-CMV-H2bGFP
(9·109 vg; Fig. 1d and Table 1) and AAV5-mCAR-
H2bGFP (>1·1010 vg)41 at PND1, indicating that
efficient transduction of immature rods is possible
at this age but dependent on the quantity of the
vector injected (Fig. 1d and Table 1).
Rod development coincides with increased
rod transduction after subretinal delivery
In mice, cones start to undergo their terminal
mitosis to begin their subsequent differentiation
before rods. Most rods in mouse are born over
an extended developmental time period (E12 to
PND5) with the peak of rod production around
birth and their differentiation into mature rods
continuing well into the postnatal period.44 To ex-
amine further how the PR transduction pattern
correlates with rod PR development, GFP expres-
Table 1. Quantification of cone and rod transduction in mouse retinas 3 weeks after subretinal injections
of different AAV vectors at different ages
Group Vector Titer (vg/mL) Strain Age Retinas analyzed % Cones (M– SD) % Rods (M– SD)
1 AAV5-CMV-dGFP 1.2· 1013 CD1 PND1 13 69.1– 7.4 2.7– 3.1
2 PND5 7 56.2– 18.3 6.0– 1.2
3 PND10 6 48.3– 6.6 18.2– 8.3
4 PND21 3 39.9– 2.2 32.2– 17.4
5 rd1 PND21 3 90.5– 4.4 NA
6 Rho-/- PND1 4 59.4– 2.9 0.09– 0.008
7 PND21 2 87.2– 7.2 0.9– 0.2
8 AAV5-CMV-H2bGFP 1.3· 1013 CD1 PND1 6 65.8– 9.7 3.2– 2.8
9 PND5 3 29.2– 1.3 2.8– 0.6
10 PND10 3 40.5– 6.6 7.4– 2.2
11 PND21 3 41.4– 13.6 21.3– 10.9
Ai9/+ PND1 3 69.5– 7.6 7.3– 1.2
12 rd1 PND21 3 84.9– 2.9 NA
13 Rho-/- PND1 2 60.3– 5.8 1.5– 0.6
14 PND21 4 81.2– 1.6 4.8– 1.7
15 AAV5-CMV-H2bGFP 5.1· 1013 CD1 PND1 2 70.3– 5.2 9.8– 4.4
16 AAV5-pQCMV-H2bGFP 1.3· 1013 CD1 PND1 6 67.2– 4.7 17.9– 26.6
Ai9/+ PND1 2 66.9– 4.7 4.4– 2.3
17 Rho-/- PND21 4 71.1– 6.6 1.2– 0.3
18 AAV5-mCAR-H2bGFP 1.3· 1013 CD1 PND1 3 51.1– 4.4 1.0– 0.4
19 AAV5-CMV-Cre 1.3· 1013 Ai9/+ PND1 5 60.6– 9.2 4.8– 1.6
20 scAAV1-CB6-eGFP 1.6· 1013 CD1 PND1 5 50.7– 10.7 8.9– 6.7
21 scAAV2-CB6-eGFP 9.8· 1012 CD1 PND1 3 47.4– 8.3 3.1– 1.4
22 scAAV3b-CB6-eGFP CD1 PND1 6 12.3– 3.6 4.3– 2.3
23 scAAV4-CB6-eGFP 1.2· 1013 CD1 PND1 3 0 0
24 scAAV5-CB6-eGFP 1.4· 1013 CD1 PND1 6 62.5– 7.8 7.2– 5.0
25 PND5 3 31.5– 9.3 14.8– 3.6
26 PND10 4 19.6– 3.3 19.6– 3.3
27 PND21 3 23.7– 5.7 38.4– 11.5
28 rd1 PND21 2 87.2– 6.2 NA
29 scAAV6-CB6-eGFP 9.8· 1012 CD1 PND1 3 50.6– 24.9 6.9– 3.3
30 scAAV7-CB6-eGFP 1.4· 1013 CD1 PND1 6 55.1– 15.3 7.2– 2.5
31 PND21 3 25.5– 5.2 34.9– 9.9
32 scAAV8-CB6-eGFP 9.1· 1012 CD1 PND1 4 57.4– 11.7 5.1– 2.0
33 PND21 8 23.3– 9.7 46.3– 8.6
34 scAAV9-CB6-eGFP 1.0· 1013 CD1 PND1 5 58.1– 13.6 6.9– 1.2
35 PND21 9 23.5– 6.7 50.3– 5.4
36 rd1 PND21 3 91.6– 2.8 NA
37 scAAVrh8-CB6-eGFP 8.1· 1012 CD1 PND1 3 57.3– 15.2 6.1– 3.3
38 scAAVrh10-CB6-eGFP 9.7· 1012 CD1 PND1 7 69.8– 12.8 6.5– 2.3
39 PND21 5 25.3– 12.4 54.8– 4.6
40 scAAVrh39-CB6-eGFP 1.0· 1013 CD1 PND1 5 61.2– 12.9 6.4– 4.7
41 scAAVrh43-CB6-eGFP 8.1· 1012 CD1 PND1 6 39.8– 9.9 4.4– 1.9
AAV, adeno-associated virus; PND, postnatal day; NA, not applicable.
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Figure 1. Photoreceptor transduction in the neonatal mouse retina by adeno-associated virus serotype 5 (AAV5) vectors. Mice injected on postnatal day 1
(PND1) were subretinally injected with similar doses of AAV2/5-CMV-dGFP, AAV2/5-CMV-H2bGFP, AAV2/5-CMV-CRE, AAV2/5-pQCMV-H2bGFP, AAV2/5-mCAR-
H2bGFP, or scAAV2/5-CB6-eGFP vectors. (a) Representative retinal flat-mounts and (c, d) cryosections 3 weeks post injection (wpi) labeled with an antibody
raised against anti-cone arrestin (CA) or with peanut agglutinin lectin (PNA; red) and counter stained with DAPI (blue: removed from 60% of panels to visualize
red and green staining better) (c,d). AAV-mediated GFP was detected by its native fluorescence (green). AAV-mediated CRE expression was detected in Ai9+
mice with the CRE-mediated expression of td-Tomato (white, native fluorescence). In retinal sections, retinal pigment epithelium (RPE) cells were artificially
removed using Photoshop. Asterisks indicate GFP+ or CRE+ (td-Tomato+) cones, while arrowheads indicate GFP+ or CRE+ (td-Tomato+) rods, which are mainly
found in the inner most rows of the outer nuclear layer (ONL). Quantitative analysis of the percentage of GFP+ or CRE+ photoreceptors in vector-exposed area
is shown in (b). Error bars represent standard deviation (SD). Numbers in bars represent the number of retina analyzed. *p < 0.05; **p < 0.01; ***p< 0.001 by
Student’s t-test. (d) After injection of higher dose of AAV2/5-pQCMV-H2bGFP, a higher number of GFP+ rods is observed throughout the ONL (representative
section). Scale bars = 25 lm. INL, inner nuclear layer; IS, inner segments; OS, outer segments; sc, self-complementary; ss, single-strand.
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Figure 2. Efficiency of cone and rod photoreceptor transduction with AAV2/5 vectors at different times after birth. AAV2/5-CMV-dGFP, AAV2/5-CMV-H2bGFP,
and scAAV2/5-CB6-eGFP were subretinally injected in mice at PND1, PND5, PND10, and PND21. In all cases, analysis was performed 3wpi. (a) Representative
retinal flat mounts (upper row) and cryosections (middle row) from mice injected with AAV2/5-CMV-dGFP and cryosections (bottom row) from mice injected
with AAV2/5-CMV-H2bGFP and immunostained for PNA or CA (red) and counterstained with DAPI (blue: removed from 60% of panels to visualize red and green
staining better). AAV-mediated GFP was detected by its native fluorescence (green). RPE cells were artificially removed using Photoshop. Dotted horizontal
lines divide the ONL in three sublayers showing that early injections (PND1 and PND5) result in the majority of transduced rods (arrowheads) located in the
most inner part of the ONL. Arrowheads indicate GFP+ rods (b). Quantification of cone, rod, and total photoreceptor transduction within the vector-exposed
area after injection of AAV2/5-CMV-dGFP and AAV2/5-CB6-eGFP at the indicated ages. Results are shown as mean– SD. **p < 0.01 and ***p< 0.001 by
Student’s t-test. (c) Average distribution of GFP+ nuclei within the ONL layer after AAV injection at the indicated ages. As shown in (a), the ONL was divided
into three sublayers: A, outermost part of the ONL; B, middle part of the ONL; C, innermost part of the ONL. The percentage of GFP+ nuclei/total nuclei (DAPI+)
was calculated. Scale bars= 25 lm.
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sion was investigated in mice injected at three ad-
ditional ages, corresponding to three different
stages of PR development: PND5 (end of PR birth
and early development of PR processes), PND10
(intermediate development of PR outer segments),
and PND21 (PR development completed; Table 1).
Injected retinas were all harvested at 3 wpi.
The histological analyses of three different AAV2/
5 vectors (Fig. 2 and Supplementary Figs. S4 and S5)
revealed a progressive shift in tropism from cones to
rods that correlated with the differentiation of the
retina. Indeed, after injection of AAV5-CMV-dGFP
(Fig. 2a and b and Supplementary Fig. S4), AAV5-
CMV-H2bGFP (Fig. 2a), or scAAV5-CB6-eGFP
(Supplementary Fig. S5a and Fig. 2b), the percent-
age of GFP+ rods increased with the age of the mouse
at the time of injection, whereas the percentage of
GFP+ cones decreased. As a result, injections of the
three vectors at PND1 and PND5 directed GFP ex-
pression predominantly in cones, while a preferen-
tial transduction of rods was observed for injections
at PND10 and PND21 (Table 1).
Interestingly, the location of GFP+ rod nuclei in
the ONL correlated with the timing of rod genesis
(Fig. 2 and Supplementary Figs. S2b, S4, and S5a).
After subretinal injection at PND1, the small per-
centage of transduced rod nuclei found was pri-
marily located in the most inner row of the ONL
where the first-born rods reside, as previously in-
dicated by birth-dating experiments45–47 (Figs. 1
and 2a and c, and Supplementary Figs. S2b, S4, and
S5a). After vector administration at PND5, while
the number of transduced rods increased, GFP+
rods were still restricted in their location to the four
or five most inner rows of the ONL (lower third of
ONL; Fig. 2a and c and Supplementary Figs. S4 and
S5a), consistent with the observation that newborn
rods are stacked on the top of the earlier born
ones.45 In contrast, injections after PND10 led to a
wide distribution of GFP+ nuclei across the ONL
(Fig. 2a and c, and Supplementary Figs. S4 and
S5a). In line with this finding, the transduction
pattern of rod and cone PRs followed the central-to-
peripheral (data not shown) and ventral-to-dorsal
gradient of PR differentiation48 when the vector
was injected at PND3 (Supplementary Fig. S5b).
Hence, the order of differentiation of PR cells is
clearly correlated with the cells preferentially
transduced after subretinal injection of AAV2/5.
Photoreceptor development affects rod
transduction, irrespective of AAV serotypes
To determine whether PR development affects
PR transduction by other AAV serotypes, neonatal
mice were subretinally injected with a panel of
13 scAAV serotypes/variants, including AAV1, -2,
-3b, -4, -5, -6, -7, -8, -9, -rh8, -rh10, -rh39, and -rh43,
all expressing eGFP under the control of the CB6
promoter (Table 1, Figs. 3 and 4, and Supplemen-
tary Figs. S6 and S7). As controls, AAV5, -7, -8, -9,
and -rh10 were subretinally injected into PND21
mice (Table 1 and Supplementary Fig. S6), as these
vectors are known to exhibit excellent tropism for
adult rods.14,15,18 Similar to the results observed
after PND1 delivery of AAV5, PND1 injections of
the all other AAVs resulted in preferential cone
transduction when considering the percentage of
GFP+ cells, with the exception of AAV4, which ef-
ficiently transduced RPE cells only (Table 1 and
Fig. 3). On average, AAVrh10 exhibited the most
efficient transduction of cones (although not sta-
tistically different from AAV5, -6, -7, -8, -9, -rh8,
and -rh39), whereas AAV3b-mediated transgene
expression was limited to sporadic RPE and PRs
(Fig. 3b). Notably, no significant difference in the
percentage of transduced rods was seen between
all the serotypes (Fig. 3). When considering the
percentage of GPF+ rods, all AAVs led to sparse rod
transduction, with most of the GFP+ rods localized
in the innermost part of the ONL (Fig. 4 and Sup-
plementary Figs. S6 and S7). Additionally, the
preferential transduction of rods observed after
subretinal injection of AAV2/5 vectors at PND21
was reproduced after injection of AAV7 (Supple-
mentary Fig. S6d and e), -8 (Supplementary
Fig. S6a, d, and e), -9 (Supplementary Fig. S6b, d,
and e), and -rh10 (Supplementary Fig. S6c–e).
Thus, rod PR development is a critical host factor
that influences AAV tropism after subretinal de-
livery independently of the serotype and thus
probably independently of the different cell at-
tachments factors utilized by each capsid.
Control of AAV transduction by photoreceptor
development depends on the injection site
Because a higher number of GFP+ rods was ob-
served after administration of higher doses of
AAV5-CMV-H2bGFP (9 ·109 vg; Fig. 1d and Ta-
ble 1) and AAV5-mCAR-H2bGFP (>1·1010 vg)41 at
PND1, the overall absence of efficient rod trans-
duction at PND1 may relate to the progressive loss
of the episomal vector genomes in rods. AAV vec-
tors integrate only at very low frequencies, and
thus vector-mediated transgene expression is pre-
dicted to diminish over time under conditions of
ongoing cellular proliferation. In transduced cones,
the number of expressed vector genomes is likely to
remain stable over time because cones are already
post-mitotic by PND1–PND5.44 In contrast, al-
though the vast majority of rod precursors are al-
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Figure 3. Predominant transduction of cone photoreceptors after the injection of 12 different AAV serotypes/variants at PND1. (a) Representative images of
retinal flat mounts at 3wpi of scAAV1, -2, -3b, -4, -6, -7, -8, -9, -rh8, -rh10, -rh39, or –rh43 vectors (all expressing eGFP under the control of the CB6 promoter), as
indicated. Labeling with PNA (red) shows expression of eGFP (green) predominantly in cones (asterisks), except for AAV4. (b) Quantification performed on
retinal flat mounts and/or cryosections of the percentage of GFP+ cones and GFP+ rods in the vector exposed area (note: actual transduction efficiency of
scAAV4 was 0% for rods and cones). Results are expressed as mean– SD. Numbers in bars represent the number of retinas analyzed. *p< 0.05; **p < 0.01;
***p < 0.001 by Student’s t-test. Scale bar= 25 lm.
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ready post-mitotic by PND144 and lineage studies
using retroviral vectors have revealed that most
rod progenitor cells that persist in the rodent retina
after birth are terminally dividing,49–51 rod pro-
genitors may dilute or lose AAV genomes, resulting
in consistent decreased transgene expression in
mature rods. Alternatively or concomitantly, the
overall absence of efficient rod transduction at
PND1 may relate to the progressive transcriptional
silencing of AAV vector DNA due to developmental
epigenetic changes. Indeed, histone modifications
have been shown to be important contributors to
gene regulation in developing rod PRs.52
To investigate these two possibilities, AAV5, -6,
-7, -8, and -9 were intravitreally injected in PND1
mice. If the factors that determine AAV tropism
during PR development are related to AAV vector
DNA, the final pattern of transgene expression
should globally be similar between the two routes
of administration. However, for all five serotypes, it
was found that rods were the predominant PR cells
transduced when the vectors were injected in-
travitreally (e.g., for AAV5: 4.2–2.6% of rods vs.
0.9– 0.3% of cones near the injection site; n = 3;
Fig. 4 and Supplementary Fig. S7). Notably, rod
nuclei expressing detectable levels of GFP were
evenly distributed across the ONL after in-
travitreal injection (Fig. 4 and Supplementary
Fig. S7), indicating that lack of efficient AAV-
mediated transduction of the late-born rods by
subretinal injections at PND1 is not due to cell di-
vision or differential silencing of the vector ge-
Figure 4. Comparative analysis of AAV vector transduction in the mouse retina after subretinal or intravitreal injection at PND1. PND1 mice injected either
subretinally (upper row) or intravitreally (lower row) with scAAV5, -6, -7, -8, or -9 expressing eGFP under the control of the CB6 promoter, as indicated.
Histological analysis was performed at 3 wpi on cryosections stained with CA (red) and counterstained with DAPI (blue). AAV-mediated GFP was detected by
its native fluorescence (green). Subretinal injections result in a higher number of transduced cones (asterisks) with most of the transduced rods (arrowheads)
located in the inner most part of the ONL (see also Figs. 1 and 2), while intravitreal injections result in scattered rods throughout the ONL and fewer transduced
cones. Scale bars= 25 lm. GCL, ganglion cell layer.
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nomes. The data suggest that factors affecting the
efficiency of AAV-mediated transduction of early
and late-born rods are site specific and likely in-
volve the access of AAV particles to the PR cells.
Receptors necessary for binding/entry of AAVs
while present in PRs may not yet be accessible on
late-born cells by AAVs from the subretinal space.
Lack of rod outer segments markedly
alters PR tropism of AAV in the adult retina
The timing of rod precursor birth (after E19) is
tightly linked to the onset of PR segment formation
and rhodopsin expression.53 To test whether the
growth of rod segments and/or the associated ma-
trix (Supplementary Fig. S8a and b) plays a role in
the access of AAV particles to PRs, an attempt was
made to visualize the distribution of AAV particles
after subretinal injection at PND1 and PND21 us-
ing anti-AAV capsid antibodies. However, the large
number of capsids present in the subretinal space
limited the analysis (data not shown). Instead,
qPCR was first employed to quantify viral binding
on PND1 and PND21 retinas after modification of
the rod IPM with neuraminidase (Supplementary
Fig. S8). Ex vivo retinal explants were used to limit
injection variability related to the surface of the
retina exposed to the vector after subretinal deliv-
ery at PND1 versus PND21. We found that the rod-
associated matrix could specifically interact with
AAV particles in vitro (Supplementary Fig. S8d).
However, these interactions were not conserved
across AAV5, -7, -8, and -9, indicating that bind-
ing of AAV to the rod IPM does not govern the
common increase in rod transduction observed
during PR development after subretinal delivery.
Next, to determine if the development of a nor-
mal rod segment plays a role in the access of AAV
particles to PRs, rod and cone transduction was
quantified in rhodopsin knockout (Rho-/-) mice54
after subretinal injection of AAV2/5-CMV-dGFP,
AAV2/5-CMV-H2bGFP, and AAV2/5-pQCMV-
H2bGFP vectors at PND1 and PND21 (Table 1 and
Fig. 5). The Rho-/- mouse is a well-characterized
model of rod-cone dystrophy that does not develop
rod outer segments.40 Importantly, this mouse
model does not display any rod degeneration during
the first three postnatal weeks. No alterations in
the IPM and outer limiting membrane (OLM)55,56
were detected in Rho-/- mice at PND21 (Supple-
mentary Fig. S9). In PND1-injected mice, the
transduction profile was similar between Rho-/-
and wild-type mice, with a preferential transduc-
tion of cone PRs (Fig. 5a and c). However, PND21
injections resulted in a fairly dramatic difference in
the final expression patterns. On average, the three
AAV vectors tested showed a similarly low trans-
duction of rod PRs in Rho-/- retinas, as seen with
PND1 injections in healthy retinas (Table 1 and
Fig. 5a and c). Rod transduction was mainly ob-
served at the site of injection near the needle tract
(data not shown). GFP+ rods were located in the
outermost part of the ONL (Fig. 5a, arrows) and
expressed qualitatively less GFP than cone PRs
(Fig. 5a and b). These observations suggest that the
presence of a sick rod segment can influence the
efficiency rod transduction upon subretinal deliv-
ery in the adult retina. Furthermore, they suggest a
potential correlation between altered rod trans-
duction and increased cone transduction.
To delineate further the influence of rods on the
efficiency of cone transduction, the rd1mouse model
was utilized, in which the vast majority of rods are
lost by PND21.57 However, in contrast to theRho-/-
retinas, the IPM is inevitably altered in this mouse
model due to the loss of rods. AAV5 or AAV9 vectors
were subretinally injected into PND21 rd1mice and
cone transduction was evaluated on retinal flat
mounts at 3 wpi (Table 1 and Fig. 5d). All vectors
resulted in dramatically enhanced cone transduc-
tion compared to control mice, considering the per-
centage of cells transduced (Table 1). The consistent
finding in two mouse models of rod degeneration
that cone transduction increases in the absence of
efficient rod transduction or in the absence of rods
suggest that rods may negatively affect cone trans-
duction in the adult mouse retina.
DISCUSSION
Gene therapy targeting PRs holds great poten-
tial for the treatment of many forms of retinal
diseases, such as retinitis pigmentosa, Leber con-
genital amaurosis, or age-related macular degen-
eration.13 A common hallmark of these diseases is
the progressive dysfunction, degeneration, and
death of PR cells. The first sign of these diseases—
visual impairment—is generally associated with
early alterations of the PRs functional structures,
the inner and outer segments, while PR cell bodies
are lost later in the process.
This study found that PR development and in-
tegrity play a major role in the efficacy of AAV-
mediated transduction after subretinal injection. It
confirmed that rod transduction increases dra-
matically during mouse postnatal retinal develop-
ment,30–34 irrespective of the AAV serotype (Fig. 1
and Supplementary Fig. S6), and showed that rod
transduction correlates with the differentiation
order of PR cells (Fig. 2 and Supplementary
Figs. S4 and S5). This effect was not due to differ-
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Figure 5. Altered of AAV tropism in Rho-/- and adult rd1 mice. (a–c) PND1 and PND21 Rho-/- mice injected with similar doses of AAV2/5-CMV-H2bGFP,
AAV2/5-CMV-dGFP, or AAV2/5-pQCMV-H2bGFP. Three weeks after injection, retinas were labeled with PNA or with an antibody raised against CA (red). AAV-
mediated GFP was detected by its native fluorescence (green). Representative images after injection of (a) AAV2/5-CMV-H2bGFP and (b) AAV2/5-CMV-dGFP
at age indicated. Asterisks indicate GFP+ cones and arrowheads indicate GFP+ rods. Quantitative analysis of the percentage of GFP+ cones (black bars) and
rods (white bars) is shown in (c). Error bars represent SD. Numbers in bars represent the number of retina analyzed. **p< 0.01 and ***p< 0.001 by Student’s
t-test. (d) Retinal flat mounts of rd1 mice injected at PND21with similar doses of AAV2/5-CMV-dGFP, AAV2/5-CMV-H2bGFP, scAAV2/5-CB6-eGFP, or scAAV2/9-
CB6-eGFP and stained for CA expression (red) 3 wpi. AAV-mediated GFP was detected by its native fluorescence (green). Percentage of transduced cones for
each vector is indicated in corresponding panel as mean– SD. Scale bars= 25 lm.
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ences in promoter activity or second-strand syn-
thesis of the viral genome, which in principle could
account for the enhanced rod transduction (Fig. 1
and Supplementary Fig. S2). Neither was this ef-
fect related to the gradual exit of rod progenitors
from the cell cycle or to epigenetic/protein inhibi-
tion of the vector genomes during development,
since both early and late-born cells were efficiently
transduced at PND1 after intravitreal delivery
of AAV vectors (Fig. 4). Thus, while serotype-
independent (Figs. 3 and 4, and Supplementary
Figs. S4–S6), the effects of PR development on AAV
transduction were, however, site specific (Fig. 4).
It is possible that restriction to AAV transduc-
tion in immature rods occurs after virion inter-
nalization due to inefficient viral trafficking.
However, intracellular AAV particle trafficking
has been shown to be influenced by the viral capsid
sequence,58 which in this case seems not to be rel-
evant with regards to the common shift in tropism
between PND1 and PND21 subretinal injections.
Alternatively, the enhanced transduction of rods
during retinal development could be related to in-
creased entry of AAVs into PRs. The OLM, in which
the zonulae adherents pore size has been estimated
to be between 30 and 36 A˚,59 may impede the dif-
fusion of AAV capsids (250 A˚) to the ONL, allowing
efficient access (and thus entry) of AAV particles
mainly to PRs that have started to developed inner
segments that protrude through the OLM (i.e.,
cones and early-born rods).33 In support of this
model,33 the timing of rod precursor birth (after
E19) is known to be tightly linked to the onset of PR
segment formation and rhodopsin expression.53
Concomitantly, the development of rod outer seg-
ment may directly or indirectly correlate with in-
creased—nonspecific—entry of AAV vectors into
PRs. Indeed, a shift in the distribution of GFP+ rod
nuclei was observed when AAV5 vectors were de-
livered after PND10, which coincides with the
elongation of rod outer segments for the majority
of rods at this age (Fig. 2c). Moreover, rod trans-
duction was profoundly inhibited in adult Rho-/-
retinas (Fig. 5) that lack rod outer segment devel-
opment but still display rod inner segments that
protrude through the OLM. Of course, other fac-
tors, such as PR stress and degeneration, could
affect the expression of AAV receptors, as well as
inhibit the expression of the transgene in the dis-
eased retina. However, there is more rational evi-
dence from the observations to suggest that vector
access to PR segments is one of the host factors
governing PR transduction efficiency upon sub-
retinal delivery, in particular since at PND21,
Rho-/-retinas had no apparent loss of rod PRs or
alterations of the IPM and OLM integrity (Sup-
plementary Fig. S9).
Importantly, the idea that PR outer segments
modulate rod transduction in the adult retina does
not contradict previous reports that demonstrated
unequivocal (but transient) structural and/or func-
tional rescue of rods by AAV-mediated gene re-
placement therapy in two mouse models of retinitis
pigmentosa that fail to develop rod outer seg-
ments; namely the Rho–/–16,60 and the Phrp2–/–61,62
mice, In the Rho-/- mice, therapeutic vectors were
injected into neonatal mice and mice younger than
PND5—two time points that precede rod outer seg-
ment growth in wild-type mice and where it has been
shown that rod transduction is dependent on the
viral load injected (Fig. 1d). In the Phrp2-/- mice, it
has been notably shown that there was a significant
difference in the number and quality of outer seg-
ment rescue in treated retinas. Depending on the
age at which the mice were treated, fewer outer
segments developed normally, with the best results
obtained in younger animals, despite the relatively
slow rate of PR death in that model. Moreover, par-
ticular differences in the infectivity of the vector
preparations and the presumed vector titers may
exist between all these studies, making it difficult to
cross-compare them directly. The goal of this study
was to determine host cell factors that influence
PR transduction, and oversaturating the system
with AAV vectors would have been counterproduc-
tive in this case. As mentioned, it has previously
been shown in wild-type mice that the majority of
immature rods in addition to inner nuclear layer
cells can be transduced by subretinal injection at
PND1 if a higher dose of vector is used (Fig. 1d).41 In
this study, the rate of rod transduction after injec-
tion at PND21 was limited to 30–55%, while other
groups have reported PR transduction rates of >90%
within the vector exposed area.14,17 Thus, the over-
all lower transduction in this study can easily ex-
plain why inRho-/- mice such a large difference with
PND21 subretinal injections was seen. Another fac-
tor that complicates the comparison between ex-
periments in the Rho-/- mice and the previously
published results by Palfi et al.16,54,60 is that the
present study used different Rho-/- mice.40 Strain
background differences between the two strains and
the way both knockout strains were generated could
have exacerbated the effect of the lower transduction
rate used to perform this study. In this regard, it is
interesting to note that the group of Jean Bennett
has also reported difficulties in transducing effi-
ciently rods in the same Rho-/- model that was used
in this study63 (Dejneka NS et al., ARVO Annual
Meeting Abstract, 2002).
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The present findings provide important informa-
tion regarding the effects of subretinal gene therapy
in animal models of PR dystrophies. First, the results
indicate that the time of intervention affects the effi-
cacy of AAV transduction if gene therapy is applied
before the full development of the retina. However, in
several mouse models of PR dystrophies, the degen-
eration of PRs is so fast that most gene therapy at-
tempts have been conducted during the first week of
life13 due to the relative slow onset of AAV-mediated
transgene expression.28 For instance, in the nmf363
murine model of PDE6a-deficiency, no apparent PR
degeneration is observed at PND12, but by PND14,
30% of PRs are already lost and only one row of PR
nuclei remains in the ONL by PND38.64 In this
model, injection of an AAV8(Y788F)-RHO-mPde6aat
PND5 resulted in an initial loss of cells between 1 and
2 months of age, followed by a preservation of three to
four rows of PR nuclei in the vector-exposed area, for
at least 6 months.65 However, the overall rod func-
tional rescue was too low to make a detectable dif-
ference by electroretinography.65 Notably, mid-stage
intervention at PND21 achieved similar efficacy as
PND5 treatment,despite loss of approximately half of
PRs at the time of injection,66 indicating that the ef-
ficacy of PND5 treatment may have been limited by
the efficient transduction of rods when compared to
the PND21 intervention. As well, another study re-
ported that subretinal injection of AAV2/5-smCBA-
mPde6b vector (1·1010 genome copies) in rd10 mice
at PND4 (before the onset of PR dystrophy) or PND21
(after the onset of PR dystrophy) resulted in similar
(partial) therapeutic effects.67
Second, the results indicate that if PR integrity
determines the ability of AAV vectors to target the
PRs, the spatio-temporal kinetics of retinal degener-
ation, the site of injection, and the health status of the
retina at the time of treatment are also important
factors affecting the overall efficacy of transduction.
For instance,murine64,68–73 andcanine74–77 modelsof
severe PR dystrophies show significant loss of PR
segments at early stages of the disease. In these
models, most preclinical studies have demonstrated
improved PR survival only when gene therapy is ap-
plied before or at very early stages of retinal degen-
eration.13,23,78–84 Moreover, when gene therapy has
been applied at later stages of the disease, the pro-
portion of PRs that were not responding to the
treatment (‘‘silent’’ cells) increased within the vector-
exposed area.1,23,85 It has been first suggested that
there is a threshold of accumulated changes after
which PR death is inevitable.1 However, recent data
indicate that continued PR loss may instead reflect
insufficient transduction efficiencies.29 An intriguing
possibility is that AAV vectors might not efficiently
access and infect subpopulations of deteriorated PRs.
Thus, early alterations of PRs may be associated with
a higher heterogeneity of transduction within the
vector-exposed area (e.g., 40% of PRs expressing high
levels of transgene and 60% of PRs expressing low
levels of transgenes rather than 100% of PRs ex-
pressing medium levels of transgene). An important
step in approaching this problem will be to under-
stand the longitudinal changes that occur during
phases of PR stress/degeneration at the level of
both the PRs and AAV vector pharmacology. Future
studies will also have to be designed to determine
whether a temporal disruption of the OLM86 and
higher doses of vectors may be able to overcome this
hurdle. Finally, delineating the relationship between
PR development, AAV trafficking, and cell receptor
usage will be essential toward developing a complete
understanding of PR transduction upon subretinal
injection.
It did not escape the authors’ attention that the
results support the notion that rods and cones may
directly or indirectly compete for AAV access.
Preclinical studies with several AAV serotypes
have established that subretinal injection in adults
often results in dominant transduction of rods
within rod-rich retinas.15,19–22,42,87 For instance, in
wild-type mice (cone:rod ratio of 1:30), while fairly
high transduction of rods is observed after sub-
retinal injection of AAV2/8, cone transduction is
restricted to only 1–12% of cells.15 In pigs, AAV2/8
mediates 3.8- to 5- and 1.7-fold higher levels of PR
transduction than AAV2/5 and AAV2/9, respec-
tively.15,22 However, all serotypes transduce the
same percentage of cones in the cone-enriched vi-
sual streak (cone:rod ratio of 1:3 to 1:5), with up to
9.2% of cones readily transduced.15 In dogs, AAV2/5
also preferentially targets rods,42 though signifi-
cant cone transduction is observed in cone-enriched
areas,23 with the use of high doses of vectors.43
Primate studies with seven different AAV serotypes
reported similar findings with weak cone trans-
duction in the rod-rich parafoveal region (1–10%),
even in the presence of ample rod PR transduction,
and with higher levels of cone transduction (20–
50%) in the pure-cone fovea.19–21,87
Consistent with the notion that there is a devel-
opmental effect in which access by AAV to cone PRs
becomes restricted, a profound decrease in cone
transduction was observed in the developing mouse
retina (Fig. 2). These observations appear to corre-
late with the increase in rod transduction (Fig. 2b).
Moreover, cone transduction was significantly en-
hanced after subretinal injection of AAV vectors in
PND21 Rho-/- (Fig. 5a–c) and rd1 mice (Fig. 5d), in
which rod transduction was inhibited by the absence
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of a healthy rod segments or by the loss of the vast
majority of rod cells at the time of treatment. Al-
though comprehensive analysis will be required to
elucidate the details of PR transduction upon sub-
retinal injection, it should be noted that there is no
evidence from the present observations to suggest
that AAV particles use different receptors between
rods and cones. Indeed,a similar shift in tropism was
observed for all tested AAV serotypes (Fig. 3 and
Supplementary Fig. S6). It is possible that the den-
sely stacked rod outer segments form physical bar-
riers between the site of delivery and the cones.
Concomitantly, cone matrix sheaths located around
cone inner and outer segments may form a barrier
that selectively reduces access of AAV particles to
the cones. Interestingly, a recent study in the feline
retina has shown that unlike mice and nonhuman
primates, cone PRs were more efficiently transduced
than rods.26 The reasons for this difference in cel-
lular tropism remain unknown, but the cone matrix
sheath of the cat differs significantly from other
mammalian species.88 In primates, only AAV9 was
shown to target cones both centrally and peripher-
ally efficiently at low doses when directly compared
to five other AAV serotypes.20 It has been hypothe-
sized that this property is due to the abundance of
terminal galactose, the cell receptor for AAV9 on the
cone PR matrix.20
The notion that rods and cones compete for AAV
transduction emphasizes the need of evaluating
components of AAV vectors planned for humans in
models that accurately depict physiological char-
acteristics of the human retina (i.e., large animals
and all-cone murine retinas).15,20–23,42,43,89,90 In-
deed, while in humans macular cones will often be
the primary treatment area, the ability of AAV
vectors to transduce the cones and restore their
function is often evaluated in murine models of PR
dystrophies that do not display a cone-enriched
area but a high rod:cone ratio. It also indicates that
loss of rod PRs associated with many forms of re-
tinopathies could be exploited to redirect AAVs
commonly toward cones.
ACKNOWLEDGMENTS
We are grateful to Christian Mueller (UMASS
Medical School) for insightful discussions and
critical reading of the manuscript; to Qin Su
(UMASS Medical School) and the Vector Core of
the Horae Gene Therapy Center for the produc-
tion of the scAAV-CB6-eGFP vectors; to Sourav
Choudhury and Miguel Sena-Esteves (UMASS
Medical School) for the gift of the Pro5 and Lec2 cell
lines; and to Julio Sanmiguel (UMASS Medical
School) for the gift of the eGFP qPCR primers. This
work was supported by an unrestricted grant from
‘‘Information Recherche Retinite Pigmentaire’’ As-
sociation (L.P.) and by the US National Institutes
of Health (RO1-EY023570, C.P). L.P. also ac-
knowledges the following funding: the Fulbright/
Fondation Monahan Postdoctoral Fellowship,
the Fondation de France ‘‘Young researcher in
ophthalmology’’ Fellowship, and the Association
Franc¸aise contre les Myopathies (AFM-Telethon)
Postdoctoral Fellowship.
AUTHOR DISCLOSURE
G.G. is a founder of Voyager Therapeutics, spe-
cialized in AAV-based gene therapy for the central
nervous system, and holds equity in the company.
G.G. is an inventor of patents with potential roy-
alties licensed to Voyager Therapeutics and other
biopharmaceutical companies. No competing fi-
nancial interests exist for the remaining authors.
REFERENCES
1. Cideciyan AV, Jacobson SG, Beltran WA, et al.
Human retinal gene therapy for Leber congenital
amaurosis shows advancing retinal degeneration
despite enduring visual improvement. Proc Natl
Acad Sci U S A 2013;110:E517–525.
2. Bainbridge JW, Mehat MS, Sundaram V, et al.
Long-term effect of gene therapy on Leber’s
congenital amaurosis. N Engl J Med 2015;372:
1887–1897.
3. Bainbridge JW, Smith AJ, Barker SS, et al. Effect
of gene therapy on visual function in Leber’s
congenital amaurosis. N Engl J Med 2008;358:
2231–2239.
4. Bennett J, Ashtari M, Wellman J, et al. AAV2
gene therapy readministration in three adults with
congenital blindness. Sci Transl Med 2012;4:
120ra115.
5. Bennett J, Wellman J, Marshall KA, et al. Safety
and durability of effect of contralateral-eye ad-
ministration of AAV2 gene therapy in patients
with childhood-onset blindness caused by RPE65
mutations: a follow-on Phase 1 trial. Lancet 2016;
388:661–672.
6. Maguire AM, Simonelli F, Pierce EA, et al. Safety
and efficacy of gene transfer for Leber’s con-
genital amaurosis. N Engl J Med 2008;358:2240–
2248.
7. Hauswirth WW, Aleman TS, Kaushal S, et al.
Treatment of leber congenital amaurosis due to
RPE65 mutations by ocular subretinal injection of
adeno-associated virus gene vector: short-term
results of a Phase I trial. Hum Gene Ther 2008;
19:979–990.
8. Jacobson SG, Cideciyan AV, Roman AJ, et al. Im-
provement and decline in vision with gene therapy
in childhood blindness. N Engl J Med 2015;
372:1920–1926.
IMPACT OF RETINAL DEVELOPMENT ON AAV TRANSDUCTION 479
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f M
as
sa
ch
us
et
ts 
M
ed
ic
al
 S
ch
oo
l e
-jo
urn
al 
pa
ck
ag
e f
rom
 on
lin
e.l
ieb
ert
pu
b.c
om
 at
 08
/29
/17
. F
or 
pe
rso
na
l u
se 
on
ly.
9. Weleber RG, Pennesi ME, Wilson DJ, et al. Re-
sults at 2 years after gene therapy for RPE65-
deficient Leber congenital amaurosis and severe
early-childhood-onset retinal dystrophy. Ophthal-
mology 2016;123:1606–1620.
10. Ghazi NG, Abboud EB, Nowilaty SR, et al. Treat-
ment of retinitis pigmentosa due to MERTK mu-
tations by ocular subretinal injection of adeno-
associated virus gene vector: results of a Phase I
trial. Hum Genet 2016;135:327–343.
11. Edwards TL, Jolly JK, Groppe M, et al. Visual
acuity after retinal gene therapy for choroider-
emia. N Engl J Med 2016;374:1996–1998.
12. MacLaren RE, Groppe M, Barnard AR, et al. Ret-
inal gene therapy in patients with choroideremia:
initial findings from a Phase 1/2 clinical trial.
Lancet 2014;383:1129–1137.
13. Petit L, Khanna H, Punzo C. Advances in gene
therapy for diseases of the eye. Hum Gene Ther
2016;27:563–579.
14. Allocca M, Mussolino C, Garcia-Hoyos M, et al.
Novel adeno-associated virus serotypes efficiently
transduce murine photoreceptors. J Virol 2007;81:
11372–11380.
15. Manfredi A, Marrocco E, Puppo A, et al. Combined
rod and cone transduction by adeno-associated
virus 2/8. Hum Gene Ther 2013;24:982–992.
16. Palfi A, Chadderton N, O’Reilly M, et al. Efficient
gene delivery to photoreceptors using AAV2/rh10
and rescue of the Rho(–/–) mouse. Mol Ther
Methods Clin Dev 2015;2:15016.
17. Natkunarajah M, Trittibach P, McIntosh J, et al.
Assessment of ocular transduction using single-
stranded and self-complementary recombinant
adeno-associated virus serotype 2/8. Gene Ther
2008;15:463–467.
18. Auricchio A, Kobinger G, Anand V, et al. Exchange
of surface proteins impacts on viral vector cellular
specificity and transduction characteristics: the
retina as a model. Hum Mol Genet 2001;10:3075–
3081.
19. Vandenberghe LH, Bell P, Maguire AM, et al.
Dosage thresholds for AAV2 and AAV8 photore-
ceptor gene therapy in monkey. Sci Transl Med
2011;3:88ra54.
20. Vandenberghe LH, Bell P, Maguire AM, et al.
AAV9 targets cone photoreceptors in the nonhu-
man primate retina. PLoS One 2013;8:e53463.
21. Boye SE, Alexander JJ, Boye SL, et al. The human
rhodopsin kinase promoter in an AAV5 vector
confers rod- and cone-specific expression in the
primate retina. Hum Gene Ther 2012;23:1101–
1115.
22. Mussolino C, della Corte M, Rossi S, et al. AAV-
mediated photoreceptor transduction of the pig
cone-enriched retina. Gene Ther 2011;18:637–
645.
23. Lheriteau E, Petit L, Weber M, et al. Successful
gene therapy in the RPGRIP1-deficient dog: a
large model of cone-rod dystrophy. Mol Ther
2014;22:265–277.
24. Bruewer AR, Mowat FM, Bartoe JT, et al. Eva-
luation of lateral spread of transgene expression
following subretinal AAV-mediated gene delivery
in dogs. PLoS One 2013;8:e60218.
25. Stieger K, Colle MA, Dubreil L, et al. Subretinal
delivery of recombinant AAV serotype 8 vector in
dogs results in gene transfer to neurons in the
brain. Mol Ther 2008;16:916–923.
26. Minella AL, Mowat FM, Willett KL, et al. Differential
targeting of feline photoreceptors by recombinant
adeno-associated viral vectors: implications for
preclinical gene therapy trials. Gene Ther 2014;
21:913–920.
27. Surace EM, Auricchio A. Versatility of AAV vectors
for retinal gene transfer. Vision Res 2008;48:353–
359.
28. Vandenberghe LH, Auricchio A. Novel adeno-
associated viral vectors for retinal gene therapy.
Gene Ther 2012;19:162–168.
29. Koch SF, Tsai YT, Duong JK, et al. Halting pro-
gressive neurodegeneration in advanced retinitis
pigmentosa. J Clin Invest 2015;125:3704–3713.
30. Surace EM, Auricchio A, Reich SJ, et al. Delivery
of adeno-associated virus vectors to the fetal
retina: impact of viral capsid proteins on retinal
neuronal progenitor transduction. J Virol 2003;77:
7957–7963.
31. Pang JJ, Lauramore A, Deng WT, et al. Com-
parative analysis of in vivo and in vitro AAV vector
transduction in the neonatal mouse retina: effects
of serotype and site of administration. Vision Res
2008;48:377–385.
32. Watanabe S, Sanuki R, Ueno S, et al. Tropisms of
AAV for subretinal delivery to the neonatal mouse
retina and its application for in vivo rescue of
developmental photoreceptor disorders. PLoS One
2013;8:e54146.
33. Xiong W, Cepko C. Distinct expression patterns of
AAV8 vectors with broadly active promoters from
subretinal injections of neonatal mouse eyes at
two different ages. Adv Exp Med Biol 2016;854:
501–507.
34. Xiong W, MacColl Garfinkel AE, Li Y, et al. NRF2
promotes neuronal survival in neurodegeneration
and acute nerve damage. J Clin Invest 2015;125:
1433–1445.
35. Punzo C, Cepko CL. Ultrasound-guided in utero
injections allow studies of the development and
function of the eye. Dev Dyn 2008;237:1034–
1042.
36. Rashnonejad A, Chermahini GA, Li S, et al. Large-
scale production of adeno-associated viral vector
serotype-9 carrying the human survival motor
neuron gene. Mol Biotechnol 2016;58:30–36.
37. Grieger JC, Choi VW, Samulski RJ. Production and
characterization of adeno-associated viral vectors.
Nat Protoc 2006;1:1412–1428.
38. Ayuso E, Mingozzi F, Montane J, et al. High AAV
vector purity results in serotype- and tissue-
independent enhancement of transduction effi-
ciency. Gene Ther 2010;17:503–510.
39. Le YZ, Ash JD, Al-Ubaidi MR, et al. Targeted
expression of Cre recombinase to cone photore-
ceptors in transgenic mice. Mol Vis 2004;10:
1011–1018.
40. Lem J, Krasnoperova NV, Calvert PD, et al. Mor-
phological, physiological, and biochemical chan-
ges in rhodopsin knockout mice. Proc Natl Acad
Sci U S A 1999;96:736–741.
41. Venkatesh A, Ma S, Langellotto F, et al. Retinal
gene delivery by rAAV and DNA electroporation.
Curr Protoc Microbiol 2013;Chapter 14:Unit
14D 14.
42. Beltran WA, Boye SL, Boye SE, et al. rAAV2/5
gene-targeting to rods:dose-dependent efficiency
and complications associated with different pro-
moters. Gene Ther 2010;17:1162–1174.
43. Komaromy AM, Alexander JJ, Cooper AE, et al.
Targeting gene expression to cones with human
cone opsin promoters in recombinant AAV. Gene
Ther 2008;15:1049–1055.
44. Swaroop A, Kim D, Forrest D. Transcriptional
regulation of photoreceptor development and
homeostasis in the mammalian retina. Nat Rev
Neurosci 2010;11:563–576.
45. Mack AF, Papanikolaou D, Lillo C. Investigation of
the migration path for new rod photoreceptors in
the adult cichlid fish retina. Exp Neurol 2003;184:
90–96.
46. Mack AF, Fernald RD. New rods move before
differentiating in adult teleost retina. Dev Biol
1995;170:136–141.
47. Henderson RG, Fernald RD. Timing and location of
rhodopsin expression in newly born rod photore-
ceptors in the adult teleost retina. Brain Res Dev
Brain Res 2004;151:193–197.
48. Fei Y. Development of the cone photoreceptor
mosaic in the mouse retina revealed by fluores-
cent cones in transgenic mice. Mol Vis 2003;9:
31–42.
49. Cepko C. Intrinsically different retinal progenitor
cells produce specific types of progeny. Nat Rev
Neurosci 2014;15:615–627.
50. Turner DL, Cepko CL. A common progenitor for
neurons and glia persists in rat retina late in
development. Nature 1987;328:131–136.
51. Hafler BP, Surzenko N, Beier KT, et al. Tran-
scription factor Olig2 defines subpopulations of
retinal progenitor cells biased toward specific cell
fates. Proc Natl Acad Sci U S A 2012;109:7882–
7887.
52. Mo A, Luo C, Davis FP, et al. Epigenomic land-
scapes of retinal rods and cones. Elife 2016;
5:e11613.
53. Morrow EM, Belliveau MJ, Cepko CL. Two phases
of rod photoreceptor differentiation during rat
retinal development. J Neurosci 1998;18:3738–
3748.
54. Humphries MM, Rancourt D, Farrar GJ, et al.
Retinopathy induced in mice by targeted disrup-
tion of the rhodopsin gene. Nat Genet 1997;15:
216–219.
480 PETIT ET AL.
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f M
as
sa
ch
us
et
ts 
M
ed
ic
al
 S
ch
oo
l e
-jo
urn
al 
pa
ck
ag
e f
rom
 on
lin
e.l
ieb
ert
pu
b.c
om
 at
 08
/29
/17
. F
or 
pe
rso
na
l u
se 
on
ly.
55. Jaissle GB, May CA, Reinhard J, et al. Evaluation
of the rhodopsin knockout mouse as a model of
pure cone function. Invest Ophthalmol Vis Sci
2001;42:506–513.
56. Calame M, Cachafeiro M, Philippe S, et al. Retinal
degeneration progression changes lentiviral vec-
tor cell targeting in the retina. PLoS One 2011;
6:e23782.
57. Punzo C, Kornacker K, Cepko CL. Stimulation of
the insulin/mTOR pathway delays cone death in a
mouse model of retinitis pigmentosa. Nat Neu-
rosci 2009;12:44–52.
58. Johnson JS, Li C, DiPrimio N, et al. Mutagenesis
of adeno-associated virus type 2 capsid protein
VP1 uncovers new roles for basic amino acids in
trafficking and cell-specific transduction. J Virol
2010;84:8888–8902.
59. Bunt-Milam AH, Saari JC, Klock IB, et al. Zonulae
adherentes pore size in the external limiting
membrane of the rabbit retina. Invest Ophthalmol
Vis Sci 1985;26:1377–1380.
60. Palfi A, Millington-Ward S, Chadderton N, et al.
Adeno-associated virus-mediated rhodopsin re-
placement provides therapeutic benefit in mice
with a targeted disruption of the rhodopsin gene.
Hum Gene Ther 2010;21:311–323.
61. Ali RR, Sarra GM, Stephens C, et al. Restoration
of photoreceptor ultrastructure and function in
retinal degeneration slow mice by gene therapy.
Nat Genet 2000;25:306–310.
62. Sarra GM, Stephens C, de Alwis M, et al. Gene
replacement therapy in the retinal degeneration
slow (rds) mouse: the effect on retinal degener-
ation following partial transduction of the retina.
Hum Mol Genet 2001;10:2353–2361.
63. Liang FQ, Dejneka NS, Cohen DR, et al. AAV-
mediated delivery of ciliary neurotrophic factor
prolongs photoreceptor survival in the rhodopsin
knockout mouse. Mol Ther 2001;3:241–248.
64. Sakamoto K, McCluskey M, Wensel TG, et al.
New mouse models for recessive retinitis pig-
mentosa caused by mutations in the Pde6a gene.
Hum Mol Genet 2009;18:178–192.
65. Wert KJ, Davis RJ, Sancho-Pelluz J, et al. Gene
therapy provides long-term visual function in a
pre-clinical model of retinitis pigmentosa. Hum
Mol Genet 2013;22:558–567.
66. Wert KJ, Sancho-Pelluz J, Tsang SH. Mid-stage
intervention achieves similar efficacy as conven-
tional early-stage treatment using gene therapy in
a pre-clinical model of retinitis pigmentosa. Hum
Mol Genet 2014;23:514–523.
67. Yao J, Jia L, Khan N, et al. Caspase inhibition
with XIAP as an adjunct to AAV vector gene-
replacement therapy: improving efficacy and
prolonging the treatment window. PLoS One 2012;
7:e37197.
68. Blanks JC, Adinolfi AM, Lolley RN. Photoreceptor de-
generation and synaptogenesis in retinal-degenerative
(rd) mice. J Comp Neurol 1974;156:95–106.
69. LaVail MM, Sidman RL. C57BL-6J mice with in-
herited retinal degeneration. Arch Ophthalmol
1974;91:394–400.
70. Tansley K. Hereditary degeneration of the mouse
retina. Br J Ophthalmol 1951;35:573–582.
71. Gargini C, Terzibasi E, Mazzoni F, et al. Retinal
organization in the retinal degeneration 10 (rd10)
mutant mouse: a morphological and ERG study.
J Comp Neurol 2007;500:222–238.
72. Won J, Gifford E, Smith RS, et al. RPGRIP1 is
essential for normal rod photoreceptor outer
segment elaboration and morphogenesis. Hum
Mol Genet 2009;18:4329–4339.
73. Ramamurthy V, Niemi GA, Reh TA, et al. Leber
congenital amaurosis linked to AIPL1: a mouse
model reveals destabilization of cGMP phospho-
diesterase. Proc Natl Acad Sci U S A 2004;
101:13897–13902.
74. Parry HB. Degenerations of the dog retina. II.
Generalized progressive atrophy of hereditary or-
igin. Br J Ophthalmol 1953;37:487–502.
75. Aguirre GD, Rubin LF. Rod-cone dysplasia (pro-
gressive retinal atrophy) in Irish setters. J Am Vet
Med Assoc 1975;166:157–164.
76. Tuntivanich N, Pittler SJ, Fischer AJ, et al. Char-
acterization of a canine model of autosomal reces-
sive retinitis pigmentosa due to a PDE6A mutation.
Invest Ophthalmol Vis Sci 2009;50:801–813.
77. Beltran WA, Acland GM, Aguirre GD. Age-
dependent disease expression determines re-
modeling of the retinal mosaic in carriers of RPGR
exon ORF15 mutations. Invest Ophthalmol Vis Sci
2009;50:3985–3995.
78. Petit L, Lheriteau E, Weber M, et al. Restoration
of vision in the pde6beta-deficient dog, a large
animal model of rod-cone dystrophy. Mol Ther
2012;20:2019–2030.
79. Pang JJ, Boye SL, Kumar A, et al. AAV-mediated
gene therapy for retinal degeneration in the rd10
mouse containing a recessive PDEbeta mutation.
Invest Ophthalmol Vis Sci 2008;49:4278–4283.
80. Pang JJ, Dai X, Boye SE, et al. Long-term retinal
function and structure rescue using capsid mutant
AAV8 vector in the rd10 mouse, a model of re-
cessive retinitis pigmentosa. Mol Ther 2011;19:
234–242.
81. Sun X, Pawlyk B, Xu X, et al. Gene therapy with a
promoter targeting both rods and cones rescues
retinal degeneration caused by AIPL1 mutations.
Gene Ther 2010;17:117–131.
82. Ku CA, Chiodo VA, Boye SL, et al. Gene therapy
using self-complementary Y733F capsid mutant
AAV2/8 restores vision in a model of early onset
Leber congenital amaurosis. Hum Mol Genet 2011;
20:4569–4581.
83. Pawlyk BS, Smith AJ, Buch PK, et al. Gene re-
placement therapy rescues photoreceptor degen-
eration in a murine model of Leber congenital
amaurosis lacking RPGRIP. Invest Ophthalmol Vis
Sci 2005;46:3039–3045.
84. Koch S, Sothilingam V, Garcia Garrido M, et al.
Gene therapy restores vision and delays degener-
ation in the CNGB1(–/–) mouse model of retinitis
pigmentosa. Hum Mol Genet 2012;21:4486–4496.
85. Beltran WA, Cideciyan AV, Iwabe S, et al. Suc-
cessful arrest of photoreceptor and vision loss
expands the therapeutic window of retinal gene
therapy to later stages of disease. Proc Natl Acad
Sci U S A 2015;112:E5844–5853.
86. West EL, Pearson RA, Tschernutter M, et al.
Pharmacological disruption of the outer limiting
membrane leads to increased retinal integration
of transplanted photoreceptor precursors. Exp Eye
Res 2008;86:601–611.
87. Bennett J, Maguire AM, Cideciyan AV, et al. Stable
transgene expression in rod photoreceptors after
recombinant adeno-associated virus-mediated
gene transfer to monkey retina. Proc Natl Acad Sci
U S A 1999;96:9920–9925.
88. Fariss RN, Anderson DH, Fisher SK. Comparison of
photoreceptor-specific matrix domains in the cat
and monkey retinas. Exp Eye Res 1990;51:473–485.
89. Boye SL, Peterson JJ, Choudhury S, et al. Gene
therapy fully restores vision to the all-cone
Nrl(–/–) Gucy2e(–/–) mouse model of Leber con-
genital amaurosis-1. Hum Gene Ther 2015;26:
575–592.
90. Ye GJ, Budzynski E, Sonnentag P, et al. Cone-
specific promoters for gene therapy of achroma-
topsia and other retinal diseases. Hum Gene Ther
2016;27:72–82.
Received for publication January 24, 2017;
accepted after revision May 16, 2017.
Published online: May 16, 2017.
IMPACT OF RETINAL DEVELOPMENT ON AAV TRANSDUCTION 481
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f M
as
sa
ch
us
et
ts 
M
ed
ic
al
 S
ch
oo
l e
-jo
urn
al 
pa
ck
ag
e f
rom
 on
lin
e.l
ieb
ert
pu
b.c
om
 at
 08
/29
/17
. F
or 
pe
rso
na
l u
se 
on
ly.
